Methods of treating erectile dysfunction

Patent metadata

Field	Value
Publication number	US-2016101115-A1
Application number	US-201414892740-A
Country	US
Kind code	A1
Filing date	Aug 29, 2014
Priority date	Sep 3, 2013
Publication date	Apr 14, 2016
Grant date	—

Abstract

An active agent for use in a method of, or for use in the preparation of a medicament for, treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, is described. The active agent has the general structure of Formula I or a pharmaceutically acceptable salt thereof.

First claim

1 . A method of treating or inhibiting the development of erectile dysfunction and/or incontinence following pelvic radiation treatment in a subject in need thereof, comprising administering said subject an active agent in a treatment effective amount, wherein said active agent is a compound of Formula I:

wherein:
each R is independently selected substituted or unsubstituted aryl, heteroaryl, cycloalkyl, or heterocycloalkyl;
each A is an independently selected hydrogen, an electron-withdrawing group, or electron donating group;
M is a metal; and
Z − is a counterion;

or a pharmaceutically acceptable salt thereof.

2 . The method of claim 1 , wherein said treatment includes radiation treatment and said active agent is administered to said subject:
prior to the onset of radiation treatment of said subject, during radiation treatment of said subject, and/or following radiation treatment of said subject.

3 . The method of claim 1 , wherein said radiation treatment comprises external beam radiation, radioactive seed implantation therapy (brachytherapy), or a combination thereof.

4 . The method of claim 1 , wherein said radiation treatment is for prostate cancer, cervical cancer, colorectal cancer, bladder cancer, uterine cancer, or endometrial cancer in said subject.

5 . The method of claim 4 , wherein said prostate cancer comprises Stage I, Stage IIA, Stage IIB, Stage III, or Stage IV prostate cancer.

6 . The method of claim 1 , wherein said compound has a structure of Formula A1:

wherein:
each R is C 1-12 alkyl;
each A is, independently, hydrogen or an electron withdrawing group;
M is metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z − is a counterion.

7 . The method of claim 1 , wherein said compound has the formula:

wherein Z− is a counterion.

8 . The method of claim 1 , wherein said compound has a structure of Formula B1:

wherein:
each R is C 1-12 alkyl;
each A is, independently, hydrogen or an electron withdrawing group;
M is metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z − is a counterion.

9 . The method of claim 1 , wherein said compound has the structure:

wherein Z − is a counterion.

10 . The method of claim 1 , wherein active compound has a structure of Formula C1:

wherein:
each R is —(CH 2 ) m CH 2 OX;
m is 1 or 2;
X is C 1-12 alkyl;
each A is, independently, hydrogen or an electron withdrawing group;
M is metal selected from the group consisting of manganese, iron, copper, cobalt, nickel and zinc, and
Z − is a counterion.

11 . The method of claim 1 , wherein said compound has the structure:

wherein Z − is a counterion.

Assignees

• Biomimetix J V Llc
• Nat Jewish Health

Inventors

• Crapo James D
• Deegan Rebecca Oberley

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• C02F2103/026

  Treating water for medical or cosmetic purposes · CPC title

• C09K8/524

  organic depositions, e.g. paraffins or asphaltenes · CPC title